Nutriband Inc. (9WV.F)

4.4600 +0.0800 (+1.83%) 收市：08:14AM CEST

Nutriband Inc.

121 South Orange Avenue
Suite 1500
Orlando, FL 32801
United States
407 377 6695
https://nutriband.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Serguei Melnik	Founder, President, Company Secretary & Executive Chairman of the Board	161.22k	無	1974
Mr. Gareth Sheridan	Founder, CEO & Director	161.22k	無	1990
Mr. Gerald Goodman	CFO & Chief Accounting Officer	128.98k	無	1948
Dr. Alan Smith Ph.D.	COO & President of 4P Therapeutics	146.48k	無	1966
Dr. Jeffrey Patrick Pharm.D.	Chief Scientific Officer	無	無	1970
Mr. Michael Myer	President of Pocono Pharmaceutical	37.4k	無	1985
Mr. Tyler Overk	Head of Active Intelligence	無	無	1984

截止 2024年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

公司管治

截至 無 止，Nutriband Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。